TKNO ALPHA TEKNOVA INC

Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

Teknova Announces Opening of New GMP-Certified Facility, Increasing Manufacturing Capacity for Custom, High-Quality Life Sciences Reagents

State-of-the-art facility in Hollister, California is designed to help bioprocessing and gene therapy companies scale from research to clinical production

HOLLISTER, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the opening of their newest GMP-certified production facility, enabling bioprocessing and gene therapy companies to get into the clinic faster.

Located in Hollister, California, the Company’s state-of-the-art modular manufacturing facility recently received ISO 13485:2016 certification for the production of GMP-grade products. Previously operational for research-grade production, the new facility adds more than 10,000 square feet of GMP-certified ISO cleanrooms and provides a three-fold increase in overall manufacturing capacity.

“Our team has worked tirelessly over the past two years to build our new GMP-certified production facility here in Hollister and its opening represents a momentous milestone in our company’s evolution,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “We kept hearing from our customers that they wanted a partner who could support them with custom reagent manufacturing as they scale from research, through process development, and into clinical trials, particularly in batch volumes of less than 2,000 liters. We built this facility to do just that – in the city we’ve called home for almost 20 years – and we look forward to leveraging our facility's modular manufacturing capabilities to continue supporting our customers throughout various stages of their lifecycle.”

“The San Benito County Chamber of Commerce is thrilled to congratulate Teknova on the opening of their latest manufacturing facility in Hollister, California,” said Michelle Leonard, Chief Executive Officer of the San Benito County Chamber of Commerce. “As a leading employer and long-time partner in the County, we’re incredibly appreciative of the investment they continue to make in Hollister, providing essential jobs to the area, and increasing our visibility as a key location for the biotech and pharmaceutical industry.”

With expanded formulation, dispensing, cleanroom, and warehouse space – including increased automation to support single-use needs and animal-free and endotoxin-controlled environments – the new GMP-certified facility exemplifies Teknova’s modular manufacturing platform, further enabling the flexible, scalable, and consistent production of high-quality reagents that the Company is known for. Bioprocessing and gene therapy companies are now able to work with one trusted partner across the entire clinical pipeline, accelerating their breakthroughs as they transition from RUO to GMP.

For more information, or to schedule a tour of Teknova’s new, GMP-certified facility, visit .

ABOUT TEKNOVA  

Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 200,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.



Investor Contacts
Matt Lowell
Chief Financial Officer
 
 

Sara Michelmore
MacDougall Advisors
 
 

Media Contact
Jennifer Henry  
Senior Vice President, Marketing 
   
  
EN
09/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, ...

 PRESS RELEASE

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2...

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025 HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. ...

 PRESS RELEASE

Teknova Reports First Quarter 2025 Financial Results

Teknova Reports First Quarter 2025 Financial Results First quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for...

 PRESS RELEASE

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern T...

 PRESS RELEASE

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation...

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies Innovative product line is purpose-built to streamline the manufacture of allogeneic cell therapies. Available exclusively from Teknova starting today. HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx’s PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch